EMA Guideline Recommends Placebo Arms for Short-Term Trials of Schizophrenia Drugs
The European Medicines Agency (EMA) is advising sponsors to use placebo arms, rather than active comparators, in short-term trials of schizophrenia drugs, according to a final guidance.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.